Madrid—Adding elotuzumab (Empliciti, Bristol-Myers Squibb) to lenalidomide (Revlimid, Celgene) and dexamethasone (ELd) results in durable long-term responses in patients with relapsed/refractory multiple myeloma (RRMM), according to four-year study results from the Phase III ELOQUENT-2 trial presented at the 2017 Congress of the European Hematology Association.
“These extended four-year follow-up data demonstrated that adding Empliciti to Ld (lenalidomide and dexamethasone) yielded